Edition:
United Kingdom

People: Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

13.90USD
19 Jun 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.90
Open
--
Day's High
--
Day's Low
--
Volume
400
Avg. Vol
413,743
52-wk High
$16.46
52-wk Low
$2.76

Fickenscher, James 

Mr. James E. Fickenscher serves as Chief Financial Officer, Vice President - Corporate Development of the Company. Mr. Fickenscher served as our chief financial officer and vice president, corporate development since September 2016. Prior to joining our company, Mr. Fickenscher served as the Senior Vice President, Chief Financial Officer of Antares Pharma, Inc., a specialty pharmaceutical company, from November 2014 until September 2016. Mr. Fickenscher served as Chief Financial Officer of Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from May 2005 until August 2014. From January 2000 until April 2004, Mr. Fickenscher served as Senior Vice President, Chief Financial Officer of Aventis Behring L.L.C., a wholly owned subsidiary of Aventis, predecessor to Sanofi S.A. Mr. Fickenscher joined Aventis Behring L.L.C. in 1995 as Vice President, Business Development and Strategic Planning and, from that time until 2000, also held the positions of General Manager, Japan and Vice President & General Manager, Hemophilia Business Unit. Throughout his tenure at Aventis Behring L.L.C., he was also responsible for strategic planning. Prior to Aventis Behring L.L.C., Mr. Fickenscher worked at Rhone-Poulenc Rorer, predecessor to Aventis S.A., in its Collegeville, PA and Paris, France offices and at Deloitte, Haskins & Sells, LLP, the predecessor to Deloitte & Touche LLP. Mr. Fickenscher received his B.S. at Bloomsburg University of Pennsylvania. He is a member of the American Institute of Certified Public Accountants.

Basic Compensation

Total Annual Compensation, USD 368,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 564,124
Fiscal Year Total, USD 932,124

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --